Documenting Pharmacist Intervention: A Technology-Driven Solution to Overcome Challenges


  • Murooj Shukri Medication Safety Officer, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
  • Amna Mukhtar Medication Safety/Clinical Support Pharmacy, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
  • Sahar Alsharif Pharmacy Automation and Support, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
  • Abdilahi Mohamed Clinical Pharmacy Specialist, King Faisal Specialist Hospital and Research Center, Madina, Saudi Arabia



Clinical Interventions, Documentation System, Clinical Pharmacy


Clinical pharmacist conducts multiple activities governed by the best evidence for disease management and safe medication practices. The ASHP highlighted the importance of documenting and recording clinical pharmacy interventions to prevent adverse drug events and reduce hospital length of stay. Our institution utilizes an in-house electronic documentation system (e-DS) to document clinical interventions. We aim to study the impact of enhancing the e-DS. This study is a retrospective single-center descriptive review post-implementation of in-house e-DS enhancements. Data were collected between September 2017 and December 2019 for documented interventions by clinical pharmacists for admitted patients. Fields for analysis include clinical interventions, expected outcomes of interventions, cycle time for documentation, and drug cost. Outcomes measures include several documented interventions, preventing medication errors/adverse drug events, time-saving and cost avoidance. Descriptive analysis will be performed for categorical variables. The study showed an increased number of documented interventions for preventing medication errors/adverse drug events, time-saving, and cost avoidance, with an average time-saving of 20 minutes per 10 interventions and estimated cost avoidance of 20 000 SAR per month. Study limitations include a lack of interface with EHR and non-feasibility to estimate indirect cost. Investment in documentation system optimization to reduce medication errors/adverse drug events, time-saving and cost avoidance.


Download data is not yet available.


Al-Jedai, A., & Nurgat, Z. A. (2012). Electronic documentation of clinical pharmacy interventions in hospitals. In Data Mining Applications in Engineering and Medicine. IntechOpen.

Antimicrobial Stewardship Guidance. Federal Bureau of Prisons Clinical Practice Guidelines, (2013).

Australia, P. S. o. (2018). Guidelines for pharmacists performing clinical interventions. Australian Government Department of Health. Pharmacy and government arrangements. sixth Community Pharmacy Agreement, Intro 4.

Campbell, A. R., Nelson, L. A., Elliott, E. S., Hieber, R., & Sommi, R.W. . (2011). Medications Most Commonly Involved in Clinical Pharmacy Interventions Documented by Pharmacy Students Psychiatric Medications Number of Interventions All Other Medications Number of Interventions Risperidone 25 Lisinopril 11 Divalproex 11 Warfarin 11 Lithium 10 Hydrochlorothiazide 6 Quetiapine 10 In.

Catania, H., & Catania, P. (1988). Using clinical interventions to cost-justify additional pharmacy staff. Hospital pharmacy, 23(6), 544, 546-548.

Claus, B. O., Vandeputte, F. M., & Robays, H. (2012). Epidemiology and cost analysis of pharmacist interventions at Ghent University Hospital. International journal of clinical pharmacy, 34, 773-778.

Craig, W. A., & Andes, D. R. (1995). Parenteral versus oral antibiotic therapy. The Medical Clinics of North America, 79(3), 497-508.

Criteria for Conversion of Intravenous to Oral/enteral (IV to PO) Anti-infectives, (2016).

Cyriac, J. M., & James, E. (2014). Switch over from intravenous to oral therapy: a concise overview. Journal of Pharmacology and Pharmacotherapeutics, 5(2), 83-87.

Gallagher, J., Byrne, S., Woods, N., Lynch, D., & McCarthy, S. (2014). Cost-outcome description of clinical pharmacist interventions in a university teaching hospital. BMC health services research, 14(1), 1-8.

Guideline for the intravenous to oral switch of antibiotic therapy (2008).

Hamblin, S., Rumbaugh, K., & Miller, R. (2012). Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach. Journal of Trauma and Acute Care Surgery, 73(6), 1484-1490.

Kim, Y., & Schepers, G. (2003). Pharmacist intervention documentation in US health care systems. Hospital pharmacy, 38(12), 1141-1147.

Medication monitoring: intravenous to oral therapeutic interchange program (2013).

Paladino, J. A., Sperry, H. E., Backes, J. M., Gelber, J. A., Serrianne, D. J., Cumbo, T. J., & Schentag, J. J. (1991). Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. The American journal of medicine, 91(5), 462-470.

Pharmacists, A. S. o. H.-S. (1996). ASHP guidelines on a standardized method for pharmaceutical care. Am J Health-Syst Pharm, 53(14), 1713-1716.

Pharmacy, A. C. o. C. (2014). Standards of practice for clinical pharmacists. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 34(8), 794-797.

Samp, J., Touchette, D., Marinac, J., & Kuo, G. (2014). American College of Clinical Pharmacy Practice-Based Research Network C. Economic evaluation of the impact of medication errors reported by US clinical pharmacists. Pharmacotherapy, 34(4), 350-357.




How to Cite

Shukri, M., Mukhtar, A., Alsharif, S., & Mohamed, A. (2023). Documenting Pharmacist Intervention: A Technology-Driven Solution to Overcome Challenges. American Journal of Chemistry and Pharmacy, 2(2), 27–36.